by Deb Balzer Credit: Pixabay/CC0 Public Domain According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer’s disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer’s disease by 27% compared with a placebo after 18 months of treatment. “This...
by University of Queensland UQ’s Dr David De Oliveira in the lab, testing the efficacy of PBT2 in disrupting and killing antibiotic-resistant Gram-negative bacteria. An experimental Alzheimer’s disease treatment is proving effective at treating some of the most persistent, life-threatening antibiotic-resistant bacteria. Researchers from The University of Queensland, The University of Melbourne and Griffith University have discovered...
